Comparison of remimazolam besylate to propofol on induction of monitored anesthesia care on patients undergoing hysteroscopy: a multicentered, randomized, double-blind, non-inferiority study

Abstract

Abstract Remimazolam besylate is an intravenous benzodiazepine sedative created from “soft” drugs. The purpose of this study is to evaluate whether the effectiveness of remimazolam is non-inferior to propofol in induction of monitored anesthesia care on patients undergoing BIS-guided hysteroscopy. This non-infertility study included patients aged 18 ~ 65 years with American Society of Anesthesiologists physical status I or II undergoing hysteroscopy. The 152 patients were prospectively recruited and randomized 1:1 to remimazolam and propofol groups.The results identified that the onset time of remimazolam was non-inferior to propofol. Compared with patients in Group P, MAP was significantly decreased at T1 (P < 0.05), HR was significantly increased from T3 to T5 (P < 0.05), and CO increased with significant difference at T8 in Group R (P < 0.05). Incidence of total adverse events in Group R was lower than that in Group P (P < 0.01). Compared with Group P, patients in Group R had a significantly longer awakening time and length of PACU stay (P < 0.05). As the induction time of monitored anesthesia care on patients undergoing hysteroscopy is considered, remimazolam besylate is non-inferior to propofol. Remimazolam has less inhibition on intraoperative hemodynamics and cardiac output than propofol. Our study shows the effectiveness and safety of remimazolam besylate on patients undergoing BIS-guided hysteroscopy.